Capucine Baldini
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Occupational and environmental lung diseases, Cancer Genomics and Diagnostics, Pleural and Pulmonary Diseases, Medical Imaging and Pathology Studies
Most-Cited Works
- → Mechanisms and therapeutic implications of hypermutation in gliomas(2020)685 cited
- → Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)(2017)218 cited
- → Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation(2018)141 cited
- → Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study(2019)104 cited
- → Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies(2020)82 cited
- → The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry(2021)78 cited
- → Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations(2024)73 cited
- → Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression(2018)64 cited
- → The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study(2020)59 cited
- → Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types(2020)56 cited